natgillin/translations-raw huggingface dataset:
In normal donors, dyspnoea has been reported commonly and other pulmonary adverse events (haemoptysis, pulmonary haemorrhage, lung infiltrates, and hypoxia) have been reported uncommonly.
Pri zdravih darovalcih so pogosto poročali o dispneji in občasno o drugih pljučnih neželenih dogodkih (hemoptiza, krvavitev v pljučih, pljučni infiltrati, in hipoksija).
In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, lung infiltrates, dyspnoea and hypoxia) have been reported very rarely in postmarketing experience.
Pri normalnih darovalcih so iz izkušenj po začetku trženja zelo redko poročali o neželenih pljučnih dogodkih (hemoptiza, pljučna krvavitev, pljučni infiltrati, dispneja in hipoksija).
In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, lung infiltrates, dyspnoea and hypoxia) have been reported very rarely in postmarketing experience.
Pri normalnih darovalcih so iz izkušenj po začetku trženja zelo redko poročali o pljučnih neželenih učinkih dogodkih (hemoptiza, pljučna krvavitev, pljučni infiltrati, dispneja in hipoksija).
In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, lung infiltration, dyspnoea and hypoxia) have been reported in postmarketing experience (see section 4.4).
Pri normalnih darovalcih so iz izkušenj po začetku trženja poročali o neželenih pljučnih dogodkih (hemoptiza, pljučna krvavitev, pljučni infiltrati, dispneja in hipoksija) (glejte poglavje 4.4).
in normal stem cell donors
pri normalnih darovalcih matičnih celic
in normal stem cell donors
pri zdravih dajalcih matičnih celic
in normal stem cell donors
pri zdravih darovalcih matičnih celic
In normal volunteers gender differences were found in the pharmacokinetic parameters of phenylbutyrate and phenylacetate (AUC and Cmax about 30 - 50 % greater in females), but not phenylacetylglutamine.
Pri normalnih prostovoljcih so bile med spoloma opažene razlike v farmakokinetičnih parametrih fenilbutirata in fenilacetata (vrednosti AUC in Cmax sta bili približno 30-50 % višji pri ženskah), vendar razlik ni bilo opaziti pri parametrih fenilacetilglutamina.
In normal volunteers gender differences were found in the pharmacokinetic parameters of phenylbutyrate and phenylacetate (AUC and Cmax about 30 - 50 % greater in females), but not phenylacetylglutamine.
Pri zdravih prostovoljcih so bile med spoloma opažene razlike v farmakokinetičnih parametrih fenilbutirata in fenilacetata (vrednosti AUC in Cmaks. sta bili približno 30–50 % višji pri ženskah), vendar razlik ni bilo opaziti pri parametrih fenilacetilglutamina.
In nr-Axial SpA, antibodies to golimumab were detected in 4% (4/93) of golimumab treated patients through week 16 by the EIA method.
Pri nr-aksialnem SpA so protitelesa proti golimumabu do 52. tedna z metodo EIA odkrili pri 7 % (14/193) bolnikov, zdravljenih z golimumabom.
In NSABP C-08, a phase III trial of Avastin in adjuvant treatment of patients with colon cancer, the incidence of new cases of ovarian failure, defined as amenorrhoea lasting 3 or more months, FSH level
V kliničnem preskušanju faze III (NSABP C-08) zdravila Avastin v adjuvantnem zdravljenju pri bolnikih z rakom na debelem črevesu so incidenco novih primerov okvare jajčnikov ocenjevali pri 295 predmenopavzalnih ženskah.
In NSCLC that had spread locally or to other parts of the body, Opdivo has been shown to improve the average time patients survived compared with docetaxel (another cancer medicine).
Pri nedrobnoceličnem pljučnem raku, ki se širi lokalno ali na druge dele telesa, je zdravilo Opdivo dokazano izboljšalo povprečni čas preživetja bolnikov v primerjavi z docetakselom (drugim zdravilom za zdravljenje raka).
In obese hypertensive patients who did not adequately respond to HCTZ 25 mg, add-on treatment with Rasilez 300 mg provided additional blood pressure reduction that was comparable to add-on treatment with irbesartan 300 mg or amlodipine 10 mg.
Pri debelih bolnikih s hipertenzijo, ki se niso zadostno odzvali na zdravljenje s hidroklorotiazidom 25 mg, je dodatek zdravila Rasilez 300 mg povzročil dodatno znižanje krvnega tlaka, ki je bilo primerljivo z dodatkom irbesartana 300 mg ali amlodipina 10 mg.
In obese subjects with Body Mass Index (BMI) > 40 kg/m2 but with creatinine clearance > 70 ml/min, the AUC0-∞ daptomycin was significantly increased (mean 42% higher) compared with non-obese matched controls.
Pri zelo debelih bolnikih z indeksom telesne mase (BMI) > 40 kg/m2 in z očistkom kreatinina > 70 ml/min je bila v primerjavi s kontrolnimi bolniki z normalno telesno maso AUC0-∞ daptomicina znatno višja (v povprečju za 42 % višja).
In obese type 2 diabetic patients insufficiently controlled by antidiabetic agents, data from four one- year clinical trials showed that the percentage of responders ( 10 % of body weight loss) was 11.3 % with orlistat as compared to 4.5 % with placebo.
V štirih enoletnih študijah bolnikov s preveliko telesno maso, ki so imeli z antiadiabetiki neustrezno zdravljeno sladkorno bolezen tipa II, je v skupini, zdravljeni z orlistatom, znašala odzivnost 11,3 % (opredeljena kot zmanjšanje telesne mase za 10 % ali več) v primerjavi s 4,5 % pri placebu.
In older patients (≥ 65 years old) and in patients with hepatic or renal impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.
Pri starejših bolnikih (≥ 65 let) in pri bolnikih z jetrno ali ledvično okvaro je treba koncentracijo glukoze v krvi spremljati pozorneje ter odmerek insulina aspart prilagoditi posamezniku.
In older patients, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.
Pri starejših bolnikih je treba koncentracijo glukoze v krvi spremljati pozorneje ter odmerek insulina aspart prilagoditi posamezniku.
In older patients, glucose monitoring should be intensified and the Levemir dose adjusted on an individual basis.
Pri starejših bolnikih je treba koncentracijo glukoze v krvi spremljati pozorneje ter odmerek zdravila Levemir prilagoditi posamezniku.
In older pigs, or in pigs with reduced appetite, or on restricted feed intake, inclusion levels may need to be increased to achieve target dose.
Pri starejših prašičih ali prašičih z zmanjšanim apetitom oziroma z omejenim prehranjevalnim režimom bo za doseganje tarčnega odmerka morda potrebno zvišati razmerja vsebnosti.
In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
V enem 3-letnem randomiziranem dvojno slepem kontroliranem preskušanju, v katerem so vrednotili učinkovitost in varnost zoledronske kisline pri zdravljenju pomenopavzalne osteoporoze (PMO), in sicer v odmerku 5 mg enkrat na leto v primerjavi s placebom, je bila skupna pojavnost atrijske fibrilacije pri bolnicah, ki so prejemale 5 mg zoledronske kisline, 2,5% (pri 96 od 3.862 bolnic), pri bolnicah, ki so prejemale placebo, pa 1,9% (pri 75 od 3.852 bolnic).
In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
V enem 3-letnem randomiziranem dvojno slepem kontroliranem preskušanju, v katerem so vrednotili učinkovitost in varnost zoledronske kisline pri zdravljenju postmenopavzalne osteoporoze (PMO), in sicer v odmerku 5 mg enkrat na leto v primerjavi s placebom, je bila skupna incidenca atrijske fibrilacije pri bolnicah, ki so prejemale 5 mg zoledronske kisline, 2,5 % (pri 96 od 3.862 bolnic), pri bolnicah, ki so prejemale placebo, pa 1,9 % (pri 75 od 3.852 bolnic).
In one 6-month Phase III study, ANORO demonstrated statistically significant improvements in trough FEV1 (primary endpoint) at Week 24 compared with placebo and each monotherapy component treatment arm.
V eni 6-mesečni študiji III. faze je zdravilo ANORO v primerjavi s placebom in vsako od obeh sestavin v monoterapiji po 24 tednih statistično značilno izboljšalo najnižji FEV1 (primarni opazovani dogodek).
In one 6-month Phase III study, LAVENTAIR demonstrated statistically significant improvements in trough FEV1 (primary endpoint) at Week 24 compared with placebo and each monotherapy component treatment arm.
V eni 6-mesečni študiji III. faze je zdravilo LAVENTAIR v primerjavi s placebom in vsako od obeh sestavin v monoterapiji po 24 tednih statistično značilno izboljšalo najnižji FEV1 (primarni opazovani dogodek).
In one active-comparator study, a higher percentage of patients receiving ANORO responded with a clinically meaningful improvement in SGRQ score at Week 24 (53%) compared to tiotropium (46%).
V eni študiji z aktivno primerjalno učinkovino se je s klinično pomembnim izboljšanjem seštevka SGRQ 24. teden odzval večji delež prejemnikov zdravila ANORO (53 %) kot prejemnikov tiotropija (46 %).
In one active-comparator study, a higher percentage of patients receiving LAVENTAIR responded with a clinically meaningful improvement in SGRQ score at Week 24 (53%) compared to tiotropium (46%).
V eni študiji z aktivno primerjalno učinkovino se je s klinično pomembnim izboljšanjem seštevka SGRQ 24. teden odzval večji delež prejemnikov zdravila LAVENTAIR (53 %) kot prejemnikov tiotropija (46 %).
In one arm patients received Protopic 0.03% ointment (n=121) twice a day for 3 weeks and thereafter once a day until clearance.
Ena skupina bolnikov je prejela zdravilo Protopic 0,03% (n=121), v prvih treh tednih dvakrat dnevno in nato enkrat dnevno, dokler kožne spremembe niso izginile.
In one case of overdose the patient inadvertently received 7.6 mg of eribulin (approximately 4 times the planned dose) and subsequently developed a hypersensitivity reaction (Grade 3) on Day 3 and neutropenia (Grade 3) on Day 7.
V enem primeru prevelikega odmerjanja je bolnik nenamerno prejel 7,6 mg eribulina (približno kratni načrtovani odmerek), posledično sta se razvili preobčutljivostna reakcija (3. stopnje) 3. dne in nevtropenija (3. stopnje) 7. dne.
In one case, this resulted in subclinical hepatitis which resolved after a dose interruption.
V enem primeru je to povzročilo subklinični hepatitis, ki je po prekinitvi zdravljenja izzvenel brez dolgoročnih posledic.
In one clinical study (study 1), 802 patients were treated with Constella 290 micrograms or placebo once daily for 26 weeks.
V eni klinični študiji (študija 1) so 802 bolnika 26 tednov zdravili z zdravilom Constella 290 mikrogramov ali s placebom enkrat na dan.
In one clinical study of women with hypogonadotrophic hypogonadism and an endogenous serum LH concentration below 1.2 IU/l the appropriate dose of r-hLH (lutropin alfa) was investigated.
V klinični študiji z ženskami s hipogonadotropnim hipogonadizmom in endogeno koncentracijo LH manjšo od 1,2 i.e./l, so proučevali ustrezen odmerek r-hLH (lutropina alfa).
In one clinical study there was a small (0.38 mmol/l) increase in blood glucose levels at night (3a.m.).
V eni klinični študiji je bil majhen (0.38 mmol/l) porast ravni glukoze merjene ponoči (3:00 zjutraj).
In one clinical study, baseline white cell cystine levels were 3.73 (range 0.13 to 19.8) nmol hemicystine/mg protein and were maintained close to 1 nmol hemicystine/mg protein with a cysteamine dose range of 1.3 to 1.95 g/m2/day.
V eni od kliničnih študij so bile izhodiščne vrednosti cistina v levkocitih 3,73 (razpon 0,13 – 19,8) nmol hemicistina/mg beljakovin, z odmerki cisteamina med 1,3 – 1,95 g/m2/dan pa so uspeli ohranjati koncentracijo približno 1 nmol hemicistina/mg beljakovin.
In one clinical study, growth and sexual development of paediatric patients treated with deferasirox for up to 5 years were not affected.
V eni klinični študiji rast in spolno dozorevanje pediatričnih bolnikov, zdravljenih z deferasiroksom do 5 let, nista bila motena.
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels.
V enem kliničnem preskušanju pri bolnikih z bipolarno manijo, je kombinirano zdravljenje z valproatom in olanzapinom povzročila incidenco nevtropenije 4,1 %; možen vzročni dejavnik so lahko visoke plazemske ravni valproata.
In one completed clinical study, there were 37 paediatric subjects (aged 1 to 14 years) enrolled and exposed to Revestive for a duration of 12 weeks.
V eno dokončano klinično študijo so vključili 37 pediatričnih preiskovancev (starih od 1 do 14 let) in jih za obdobje 12 tednov izpostavili zdravilu Revestive.
in one dose in association with
en odmerek, ob sočasnem zdravljenju
in one dose in association with acetylsalicylic acid
v enem odmerku, skupaj z acetilsalicilno kislin
in one dose in association with acetylsalicylic acid
v enem odmerku, skupaj z acetilsalicilno kislino
In one laboratory safety study, no adverse reactions were observed after the first injection of a single dose of vaccine to calves.
V eni študiji o varnosti pri teletih ni bilo po prvem dajanju enega odmerka opaziti nobenih neželenih škodljivih učinkov.
In one main study in 130 patients who had or were suspected to have osteomyelitis in their limbs, radiolabelled Scintimun was compared with a standard diagnostic technique using the patients’ own white blood cells that were radiolabelled before being injected back into the patient.
V eni glavni študiji so pri 130 bolnikih, ki so imeli ali je obstajal sum, da imajo, osteomielitis v okončinah, radioaktivno označeno zdravilo Scintimun primerjali s standardno diagnostično tehniko, pri kateri se radioaktivno označijo bolnikove lastne bele krvne celice, preden se injicirajo nazaj v telo.
In one main study involving 102 patients with severe VOD following blood stem-cell transplantation, Defitelio was compared with a historical control group of patients who had received standard supportive care.
V eni glavni študiji, ki je vključila 102 bolnika s hudo VOB po presaditvi krvotvornih matičnih celic, so zdravilo Defitelio primerjali s historično kontrolno skupino bolnikov, ki so prejeli standardno podporno oskrbo.
In one main study involving 665 patients with advanced gastric or gastro-oesophageal junction cancer which worsened despite treatment with medicines containing platinum and fluoropyrimidine, those treated with Cyramza and paclitaxel lived significantly longer on average than patients treated with paclitaxel and placebo (a dummy treatment): 9.6 months versus 7.4 months respectively.
V eni glavni študiji, v katero je bilo vključenih 665 bolnikov z napredovalim rakom želodca ali rakom gastro-ezofagealnega prehoda, pri katerih se je bolezen poslabšala kljub zdravljenju z zdravili, ki vsebujejo platino in fluoropirimidin, so bolniki, ki so prejemali zdravilo Cyramza in paklitaksel, v povprečju živeli bistveno dlje kot bolniki, ki so prejemali paklitaksel in placebo (zdravilo brez zdravilne učinkovine): 9,6 meseca v primerjavi s 7,4 meseca.
In one main study involving 800 patients, those treated with Lonsurf lived on average for 7.1 months compared with 5.3 months for patients who were treated with placebo (a dummy treatment).
V glavni študiji, ki je vključevala 800 bolnikov, so bolniki, zdravljeni z zdravilom Lonsurf, živeli povprečno 7,1 meseca, v primerjavi s 5,3 meseca pri bolnikih, zdravljenih s placebom (zdravilom brez zdravilne učinkovine).
In one main study, 178 adult cancer patients with breakthrough pain took one spray of either Instanyl (50, 100 or 200 microgram) or placebo (a dummy treatment) when they experienced breakthrough pain.
V eni glavni študiji je 178 odraslih bolnikov z rakom in prebijajočo bolečino prejemalo po en vpih zdravila Instanyl (50, 100 ali 200 mikrogramov) ali placeba (zdravila brez zdravilne učinkovine), ki so ga dobili ob nastopu prebijajoče bolečine.
In one main study, 65% of patients given Dexdor maintained the required level of sedation compared with 65% of those receiving propofol.
V eni glavni študiji je 65 % bolnikov, ki so prejeli zdravilo Dexdor, ohranilo želeno stopnjo sedacije v primerjavi s 65 % tistih, ki so prejeli propofol.
In one main study, Cinryze and placebo (a dummy treatment) were used to treat angioedema attacks in 71 patients with hereditary angioedema.
V eni glavni študiji so zdravilo Cinryze in placebo (zdravilo brez zdravilne učinkovine) uporabili za zdravljenje napadov angioedema pri 71 bolnikih z dednim angioedemom.
In one main study, PecFent was compared with placebo (a dummy treatment) in 83 adults with cancer who were being treated with opioids.
V eni glavni študiji so zdravilo PecFent primerjali s placebom (zdravilom brez zdravilne učinkovine) pri 83 odraslih z rakom, ki so se zdravili z opioidi.
In one main study, when dapagliflozin was used at a dose of 5 mg twice a day in addition to metformin (the same combination as in Ebymect), it decreased HbA1c (glycosylated haemoglobin) levels by 0.65% after 16 weeks, compared with a reduction of 0.30% with placebo (a dummy treatment) and metformin.
V eni glavni študiji je dapagliflozin, ki so ga uporabili v odmerku 5 mg dvakrat na dan skupaj z metforminom (enaka kombinacija kot v zdravilu Ebymect), po 16 tednih znižal ravni HbA1c za 0,65 %, medtem ko sta placebo (zdravilo brez zdravilne učinkovine) in metformin povzročila 0,30-odstotno znižanje.
In one main study, when dapagliflozin was used at a dose of 5 mg twice a day in addition to metformin (the same combination as in Xigduo), it decreased HbA1c levels by 0.65% after 16 weeks, compared with a reduction of 0.30% with placebo (a dummy treatment) and metformin.
V eni glavni študiji je dapagliflozin, ki so ga uporabili v odmerku 5 mg dvakrat na dan skupaj z metforminom (enaka kombinacija kot v zdravilu Xigduo), po 16 tednih znižal ravni HbA1c za 0,65 %, medtem ko sta placebo (zdravilo brez zdravilne učinkovine) in metformin povzročila 0,30-odstotno znižanje.
In one maintenance treatment study, patients receiving Alimta lived for a further 4.3 months from the start of maintenance treatment without their cancer getting worse, compared with 2.6 months in those receiving placebo.
V študiji vzdrževalnega zdravljenja so bolniki, ki so prejemali zdravilo Alimta živeli še 4,3 meseca od začetka vzdrževalnega zdravljenja, ne da bi rak napredoval, tisti, ki so prejemali placebo pa le
In one of the 3 pivotal studies conducted in which a median follow-up of 5.5 years was available (BCIRG006) a continuous increase in the cumulative rate of symptomatic cardiac or LVEF events was observed (up to 2.37 %) in patients who were administered Herceptin concurrently with a taxane following anthracycline therapy, compared to approximately 1 % in the two comparator arms (anthracycline plus cyclophosphamide followed by taxane and taxane, carboplatin and Herceptin).
V enem od treh ključnih preskušanj, v katerem je bila na voljo mediana časa sledenja 5,5 leta (BCIRG006), so pri bolnikih, ki so zdravilo Herceptin prejeli sočasno s taksanom po antraciklinski terapiji, opazili stalno rast v kumulativnem deležu simptomatskih neželenih učinkov, povezanih s srcem, ali neželenih učinkov, povezanih z iztisnim deležem levega prekata (LVEF) (do 2,37 %); v dveh primerjalnih skupinah (antraciklin in ciklofosfamid, ki jima je sledil taksan ali taksan, karboplatin in zdravilo Herceptin) pa je ta delež znašal približno 1 %.
In one of the main studies, around 35% of patients taking Fampyra responded to treatment compared with 8% of patients taking placebo.
V eni glavni študiji se je na zdravljenje odzvalo okoli 35 % bolnikov, ki so jemali zdravilo Fampyra, v primerjavi z 8 % bolnikov, ki so jemali placebo.
In one of the main studies, the change in pain intensity after ten minutes was between 1.8 and 2.7 points on the pain scale for patients who took Instanyl, compared with 1.4 for patients who took placebo.
V eni od glavnih študij je pri bolnikih, ki so jemali zdravilo Instanyl, sprememba v intenzivnosti bolečine po desetih minutah znašala med 1,8 in 2,7 točke na bolečinski lestvici, pri bolnikih, ki so jemali placebo, pa 1,4 točke.
In one of the studies, which involved patients with bone metastases from prostate cancer, the patients’ use of opioid analgesics (such as morphine) was also reduced following treatment with QUADRAMET.
V eni izmed študij, ki je vključevala bolnike s kostnimi metastazami zaradi rakavega obolenja prostate, je po zdravljenju z zdravilom QUADRAMET prišlo tudi do zmanjšanja uporabe opiatnih analgetikov (kot je na primer morfin).
In one of the study arms (group 2, n = 329), patients with an inadequate response were allowed to dose titrate with 1.5 mg/kg increments from 3 up to 9 mg/kg.
V enem kraku študije (skupina 2, n = 329) so bolnikom z nezadostnim odzivom na zdravilo omogočili titracijo t.j. povečevanje odmerka v korakih po 1,5 mg/kg, od 3 do največ 9 mg/kg.
In one of the study arms (group 2, n=329), patients with an inadequate response were allowed to dose titrate with 1.5 mg/kg increments from 3 up to 9 mg/kg.
V enem kraku študije (skupina 2, n=329) so bolnikom z nezadostnim odzivom na zdravilo omogočili titracijo t.j. povečevanje odmerka v korakih po 1,5 mg/kg, od 3 do največ 9 mg/kg.
In one of these studies, after an initial dose of 1.0 mg/kg every 2 weeks for 6 months, 0.3 mg/kg every 2 weeks may maintain clearance of GL-3 in certain cell types in some patients; however, the long term clinical relevance of these findings has not been established (see section 5.1).
V eni od študij lahko po začetnem odmerku 1,0 mg/kg vsaka 2 tedna v trajanju 6 mesecev, 0,3 mg/kg vsaka 2 tedna vzdržuje očistek GL-3 pri nekaterih vrstah celic in pri nekaterih bolnikih; vendar pa dolgoročne klinične pomembnosti teh izsledkov niso ugotovili (glejte poglavje 5.1).
In one of these studies, the patients were treatment-naïve, but in the other study, they had taken HIV treatment including protease inhibitors before.
V eni od teh študij se bolniki še niso zdravili zaradi okužbe z virusom HIV, v drugi študiji pa so se bolniki že zdravili in pri tem uporabljali tudi zaviralce proteaz.
In one of two studies of Mekinist in combination with dabrafenib, 423 patients were given either the combination or dabrafenib alone.
V eni od dveh študij z zdravilom Mekinist v kombinaciji z dabrafenibom je 423 bolnikov prejemalo bodisi kombinacijo obeh učinkovin bodisi samo dabrafenib.
In one of two studies of Tafinlar in combination with trametinib, 423 patients were given either the combination or Tafinlar alone.
V eni od dveh študij z zdravilom Tafinlar, uporabljenim v kombinaciji s trametinibom, je 423 bolnikov prejemalo bodisi kombinacijo obeh učinkovin bodisi samo zdravilo Tafinlar.
In one study 56% of patients given Zykadia (92 of 163) were considered by the treating doctors to have shown a complete or partial response to the medicine at the time of analysis.
V eni od študij so lečeči zdravniki v času analize za 56 % bolnikov, ki so prejemali zdravilo Zykadia (92 od 163), presodili, da so izkazali popoln ali delen odziv na zdravilo.
In one study all Eravac vaccinated rabbits survived compared with a 37% survival rate in the group that received the placebo vaccine.
V eni izmed študij so preživeli vsi kunci, cepljeni z zdravilom Eravac, v skupini, cepljeni s placebom, pa je bila stopnja preživetja 37-odstotna.
In one study involving 3,372 people, subjects were given either a seasonal flu vaccine followed by two doses of Aflunov three weeks apart, or placebo (a dummy vaccine) followed by two doses of an adjuvanted seasonal vaccine three weeks apart.
V eno študijo je bilo vključenih 3 372 preiskovancev, ki so prejeli bodisi cepivo proti sezonski gripi ter dva odmerka cepiva Aflunov v tritedenskih presledkih bodisi placebo (cepivo brez zdravilne učinkovine) ter dva odmerka sezonskega cepiva z adjuvansom v tritedenskih presledkih.
In one study linagliptin was given as add-on to metformin plus sulphonylurea.
V eni študiji so linagliptin dajali kot dodatno zdravilo ob metforinu in sulfonilsečnini.